KCNQ2 and Encephalopathy: Since most patients with KCNQ2 encephalopathy carry a heterozygous mutation, we evaluated the ability of KCNQ openers in clinical trials (RTG, HN37, and XEN1101) to rescue the function of mutations in the heteromeric configuration.